LINKER-MM4 trial shows linvoseltamab monotherapy achieves a 79% overall response rate in newly diagnosed MM patients, with 92 ...
Dr Rahul Banerjee discusses ASH 2025 and bispecific antibodies in myeloma, including data from MajesTEC-3, IFM2021-01, and IMMUNOPLANT.
Patients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab, a bispecific ...
New research reveals teclistamab and daratumumab significantly enhance progression-free survival in multiple myeloma, ...
Dr. Amany Keruakous sat down for an interview with CURE, in which she discussed how bispecific antibodies for multiple ...
In a step forward for bispecific antibodies, study results presented at ASH suggest a Tecvayli-based combination could have ...
In this installment of The OncoloGIST, Hans Lee, MD, director of Myeloma Research at Sarah Cannon Research Institute, ...
Annual Meeting, held December 6-9, 2025, in Orlando, Florida, showcased groundbreaking clinical advances in multiple myeloma ...
Bispecific antibodies target specific cells, offering effective treatment for relapsed/refractory multiple myeloma, with varying side effect profiles. Bispecific antibodies are a type of immunotherapy ...
The "United States Multiple Myeloma Market Report by Drugs Types, Disease Types, End User, States and Company Analysis, 2025-2033" has been added to ResearchAndMarkets.com's offering.The United States ...
In multiple myeloma, plasma cells proliferate uncontrollably in the bone marrow, disrupting the growth of healthy ...
Multiple myeloma (MM) is a life-threatening hematological malignancy. High-dose chemotherapy followed by autologous stem cell transplantation is a relatively effective treatment, but disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback